Medicare, Medicaid and GLP-1s in 2026: The Real Coverage Map

Because of a single sentence written in 2003.

The Medicare Modernization Act, which created Part D, listed categories of drugs that Part D plans may exclude from coverage. One of those categories is "agents when used for anorexia, weight loss, or weight gain." At the time, the weight loss drug landscape was dominated by products with poor efficacy and a history of safety problems, and Congress simply carved them out.

That sentence has outlived its context by more than two decades. It is the reason a 68-year-old with a BMI of 38 and knee osteoarthritis is told her Part D plan cannot cover Zepbound, while her 63-year-old neighbour on commercial insurance gets it approved.

Two important nuances people miss.

First, the exclusion is about the indication, not the molecule. The statute says "when used for" weight loss. The same semaglutide molecule that is excluded when prescribed for obesity is covered when prescribed for type 2 diabetes. This is why the FDA-approved indication on your prescription matters more than anything else in the entire process.

Second, the exclusion is statutory, not regulatory, which means CMS cannot simply decide to cover obesity drugs. In November 2024 the outgoing administration proposed a rule reinterpreting the exclusion to permit coverage of anti-obesity medications under Part D and Medicaid. In April 2025 CMS declined to finalize it, citing cost. Subsequent policy announcements have proposed negotiated-price pathways for Medicare and Medicaid beneficiaries, but implementation has moved in stages and specifics have shifted more than once.

Verify current status directly with your plan. This is an area where policy has changed repeatedly and where a blog post published today can be out of date by the next plan year.

Three, and knowing them precisely is the single most useful thing in this article.

Type 2 diabetes. The oldest and most straightforward pathway. Ozempic (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved for type 2 diabetes and are covered on most Part D formularies, typically at a specialty or non-preferred brand tier with prior authorization. If you have a documented type 2 diabetes diagnosis, this is a normal, uncontroversial coverage request.

Cardiovascular risk reduction. In March 2024 the FDA approved Wegovy (semaglutide 2.4 mg) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity. The approval was based on the SELECT trial (NEJM 2023), which found a 20 percent reduction in major adverse cardiovascular events over an average of about 40 months. CMS confirmed shortly afterward that Part D plans may cover Wegovy for this indication, because it is no longer "used for weight loss." You need documented established cardiovascular disease, which typically means prior heart attack, prior stroke, or peripheral arterial disease.

Obstructive sleep apnea. In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. This opened a third Part D pathway. It requires a sleep study documenting moderate-to-severe OSA. We covered the trial results in detail in [what SURMOUNT-OSA found](/blog/glp1-sleep-apnea-surmount-osa-tirzepatide-results).

What this means practically: the conversation with your prescriber should start with which indication you qualify for, not which drug you want. A woman with obesity and untreated sleep apnea has a coverage route that a woman with obesity alone does not, and the difference is a sleep study she may not have had.

A caution worth stating plainly: do not ask a clinician to write a diagnosis you do not have. That is fraud, it puts your prescriber's license at risk, and it can void your coverage retroactively. The point is to identify conditions you genuinely have and may not have been formally worked up for.

Because federal law prohibits it, and this catches almost everyone off guard.

The federal Anti-Kickback Statute bars manufacturers from offering anything of value to induce the purchase of a product reimbursed by a federal healthcare program. Copay assistance from a drug manufacturer counts as something of value. So the moment you enroll in Medicare, the $25-a-month savings card you may have been using on commercial insurance becomes unavailable to you. Every manufacturer savings program excludes patients enrolled in Medicare, Medicaid, TRICARE and VA benefits, and this is stated in the fine print.

This is one of the more painful transitions in American healthcare: turning 65 can cost you a benefit you had at 64.

What is still available to Medicare beneficiaries:

Independent charitable foundations. Unlike manufacturer programs, certain 501(c)(3) patient assistance foundations may help Medicare patients, provided they are independent of the manufacturer and operate under OIG advisory opinion guidance. They are typically income-limited and fund-dependent, and funds open and close through the year.

Manufacturer patient assistance programs (PAPs). Distinct from copay cards. These provide free medication to low-income patients, and some do accept Medicare beneficiaries who meet income criteria and lack coverage for the drug. Novo Nordisk and Eli Lilly both operate PAPs. Application is paperwork-heavy and income-verified.

The Medicare Prescription Payment Plan. Introduced under the Inflation Reduction Act, this lets you spread your Part D out-of-pocket costs evenly across the calendar year rather than paying a large amount in January. It does not reduce what you pay in total, but it fixes the cash flow problem that causes many people to abandon a prescription at the start of the year.

The Part D out-of-pocket cap. Also from the IRA, this caps annual out-of-pocket Part D spending, which fundamentally changed the math for anyone on a high-cost specialty drug. Once you hit the cap, covered drugs cost you nothing for the rest of the year.

Extra Help (Low-Income Subsidy). If you qualify by income and assets, this dramatically reduces Part D premiums, deductibles and copays. It is significantly underclaimed.

For cash-pay routes outside insurance entirely, see [GLP-1 direct-pay prices in 2026](/blog/glp1-direct-pay-pricing-2026-lillydirect-novocare-trumprx).

It depends entirely on your state, and the picture has been moving in both directions.

Medicaid operates differently from Medicare here. The same 2003 exclusion applies to weight loss drugs as an optional exclusion for state Medicaid programs, which means states may choose to cover anti-obesity medications if they want to. Roughly a dozen states have chosen to do so, though the exact count changes as budgets shift.

What varies by state:

• •Whether obesity is a covered indication at all
• •BMI thresholds, commonly 30, or 27 with a comorbidity
• •Prior authorization requirements, often including documented participation in a lifestyle intervention program for 3 to 6 months
• •Step therapy, requiring you to fail an older, cheaper agent first
• •Preferred product, which may mean only one of semaglutide or tirzepatide is on the list
• •Continuation criteria, typically requiring documented weight loss of 5 percent by a set point to renew

The direction of travel has not been uniformly positive. Several states and state employee health plans have narrowed or eliminated coverage after budget overruns, and public employee plans in particular have made high-profile cuts.

Diabetes coverage under Medicaid is far more consistent. Essentially all state Medicaid programs cover GLP-1 agents for type 2 diabetes, subject to prior authorization and preferred drug list rules.

How to find out for your state: search for your state's Medicaid "preferred drug list" or "PDL" plus the drug name. These documents are public, updated quarterly, and specify the exact prior authorization criteria. Your pharmacist can also run a test claim, which takes about two minutes and tells you definitively whether it will pay.

If you get denied, the appeal process is real and frequently successful. Our [guide to appealing a GLP-1 denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) walks through the letter, the documentation, and the escalation path.

Yes, and they are underused for this.

GLP-1 medications prescribed for type 2 diabetes are unambiguously eligible medical expenses under IRS rules. No extra documentation beyond the prescription is typically needed.

GLP-1 medications prescribed for weight loss occupy a more specific category. Under IRS Publication 502, weight loss program costs are deductible medical expenses when the weight loss is treatment for a specific disease diagnosed by a physician, including obesity itself. In practice this means you should obtain a Letter of Medical Necessity from your prescriber stating the diagnosis and that the medication is prescribed to treat it. Most FSA and HSA administrators accept this. Keep it in your records.

A note for Medicare enrollees: you cannot contribute new money to an HSA once you enroll in any part of Medicare, but you can still spend down an existing HSA balance on qualified expenses, including prescriptions. That existing balance is one of the few tax-advantaged tools still available to you.

One more piece of practical arithmetic that people skip. If you are looking at a high monthly cash cost, compare it against:

• •The list price with a manufacturer direct-pay program
• •The price for a lower dose, since some direct-pay programs price by dose
• •Whether a different molecule with a coverable indication would work for you

The difference between routes can be several hundred dollars a month for the same person, and the deciding variable is usually paperwork rather than medicine. For a full breakdown of the brand versus compounded question in the current regulatory environment, see [compounded vs brand GLP-1: what changed in 2026](/blog/compounded-vs-brand-glp1-what-changed-2026).

Finally, this whole landscape changes with each plan year and each policy announcement. Re-check in October during open enrollment, when Part D formularies for the coming year are published and you can compare plans specifically on their GLP-1 tiering.